Pulmonary Surfactant Market Growth Opportunities, Driving Factors by Manufacturers, Regions, Type and Application, Forecast Analysis to 2026
Pulmonary
surfactant is a complex mixture of phospholipids and proteins that creates a
unique interface separating alveolar gas and liquids at the alveolar cell
surface, reducing surface tension, and maintaining lung volumes at end
expiration. Reduction of the surface tension at the air–liquid interface is a
requirement for respiratory function following birth. Deficiency of pulmonary
surfactant causes respiratory failure in premature infants, or infantile
respiratory distress syndrome (IRDS). The adequacy of pulmonary surfactant is
maintained by unique and highly regulated systems mediating the synthesis,
secretion, reutilization, and catabolism of surfactant. Loss or inactivation of
pulmonary surfactant later in life occurs in the adult respiratory
distress syndrome (ARDS), a significant cause of morbidity and mortality
following infection, shock, or trauma. Mutations in genes regulating surfactant
homeostasis, including SFTPA, SFTPB, SFTPC, ABCA3, TITF1, and CSF2RA cause
acute and/or chronic lung disease in newborn infants, children, and adults.
Disorders of GM-CSF signaling inhibit surfactant lipid and protein catabolism
by alveolar macrophage causing pulmonary alveolar proteinosis (PAP).
Global pulmonary surfactant market
size was valued at US$ 578.7 million in 2022 and is expected to witness a
CAGR of 4.50 % over the forecast period (2022 – 2030).
Pulmonary Surfactant Market-Drivers
Increasing preference of animal derived surfactant for the treatment of
respiratory distress syndrome is driving the pulmonary
surfactant market growth over the forecast period.
Increasing preference of animal derived surfactant for the treatment of
respiratory distress syndrome is driving the pulmonary surfactant market growth
over the forecast period. For instance, in May 2021, according to the article
published in Archives of Clinical and Medical Case Reports, an open access,
peer reviewed Journal, Poractant alfa (Curosurf), significantly reduced the
rates of pneumothorax (the presence of air or gas in the cavity between the
lungs and the chest wall, causing collapse of the lung) in preterm infants with
respiratory distress syndrome. This reduction was more significant in VLBW
(very low birth weight) than non-VLBW (very low birth weight) infants.
Furthermore, on April 11, 2022, an article was published in National
Center for Biotechnology Information, a branch of the National Institutes of
Health, which reported that when animal derived pulmonary surfactant is combined
with budesonide, a corticosteroid or steroid, in the treatment of neonatal
respiratory distress syndrome can effectively shorten the hospital stay and
reduce the time of invasive mechanical ventilation and the incidence of BPD
(bronchopulmonary dysplasia). Meanwhile, it does not increase the risk of
related complications or death. This approach can be applied clinically.
Comments
Post a Comment